Skip to main content
Janssen's Zytiga approved for castration-sensitive prostate cancer

Johnson & Johnson unit Janssen Pharmaceuticals' Zytiga, or abiraterone acetate, in combination with prednisone was approved by the FDA as a treatment for patients with metastatic high-risk castration-sensitive prostate cancer. The drug, which was previously approved for patients with late-stage prostate cancer, reduced the risk of death by 38% versus placebo use in a late-stage study for CSPC patients.

Full Story: